Pharmacogenetic Testing

Clinically Actionable Pharmacogenetic Tests to Determine Right Medication and Dosage

Pharmacogenetic Testing allows us to assess the likelihood that an individual will have normal, reduced or enhanced response to certain medications. This is very important because it dictates how a person responds to a treatment prior to actually receiving the treatment based on genetics, improving efficacy and reducing adverse effects.

Actionable Pharmacogenetic Biomarkers Identify Genetic Fingerprints to Help Determine the Tailored Treatment Plan

ABCB1
APOE
COMT
CYP2C19
CYP2C9
CYP2D6
CYP1A2
CYP2B6
CYP3A4
CYP3A5
DRD2
Factor II
Factor V
MTHFR
OPRM1
SLCO1B1
VKORC1
ApoE
CYP2C9
CYP2D6
CYP3A4
CYP3A5
CYP1A2
ABCB1
CYP2B6
CYP2C19
SLCO1B1
VKORC1
Factor II
Factor V
MTHFR
CYP2B6
DRD2
CYP1A2
OPRM1
CYP2D6
CYP3A4
COMT
CYP2C19
CYP3A5
CYP2C9
CYP2C19
CYP3A4
CYP2C9
CYP1A2
CYP2D6
CYP3A5
OPRM1
COMT
CYP2C19
CYP3A5
CYP2C9
CYP2D6
MTHFR
Factor II
Factor V
VKORC1
Factor II
Factor V
MTHFR

Tests can be ordered as a panel, or individually. Customized report with personalized results.

Adverse drug reaction (ADR) is the number four leading cause of death, with cardiac disease the first, cancer the second, and accidents as the third. It is estimated that about 2.2 million hospitalized patients suffer from ADR, resulting in 106,000 annual deaths. One of the causes for ADR is failed drug metabolism that could result in inactive products, leading to therapy failure or toxic metabolites that linger in the body for a longer time, which then lead to adverse side effects.
Pharmacogenetic Testing is shown to provide tailored information for the right medication for a person based on their genetic makeup and to enhance drug efficacy. It allows us to assess the likelihood that an individual will have a normal, reduced, or enhanced response to certain medications. This is very important because it dictates how a person responds to a treatment prior to actually receiving the treatment based on their genetics, improving efficacy and reducing adverse effects

Medical Management

Comprehensive Drug Metabolism Panel

Purchase Medical Management Test Kit
This test may aid in drug selection and dose planning for drugs metabolized by genes in our comprehensive Medical Management Panel: opioid analgesics (buprenorphine, fentanyl, hydrocodone, meperidine, methadone), other common drugs (clonazepam, statins), plavix, warfarin (coumadin), antidepressants, antipsychotic medications, antimalarials, clopidogrel, diazepam, phenytoin, proton pump inhibitors, tamoxifen, beta blockers, anti-arrhythmic, morphine derivatives, xenobiotics, anti-cancer drugs cyclophosphamide and ifosphamide, NNRTI, opiate replacement therapy, anesthetic, protein kinase inhibitor, SERM, catecholamine neurotransmitters dopamine, epinephrine, and norepinephrine. It also detects gene variants that affect pain threshold, presence of pain-related disorders (fibromyalgia, TMJ syndrome, migraine), in addition to variants associated with inherited thrombosis.
ABCB1
APOE
COMT
CYP2C19
CYP2C9
CYP2D6
CYP1A2
CYP2B6
CYP3A4
CYP3A5
DRD2
Factor II
Factor V
MTHFR
OPRM1
SLCO1B1
VKORC1

Cardiac

And Blood Clot Panel

Purchase Cardiac and Blood Clot Test Kit
This test targets the genotyping of 11 genes that are known to affect the metabolism of medications that treat cardiovascular disease and may aid in drug selection and dose planning for drugs metabolized by genes in the Cardiac Panel, including gene variants that affect Beta Blockers, Antiplatelets, Anticoagulants, Statins, Antiarrhythmics, and others.

This panel also checks for the risk of thrombosis based on genotyping of common variants in three genes: Factor II, Factor V, and Methylenetetrahydrofolate reductase (MTHFR). The presence of inherited thrombophilia does not affect anticoagulant therapy since the mutations tested for are not known to be resistant to therapy; however, they may recommend the prolonged use of anticoagulants during therapy, especially for patients that would alternatively stop the medication without this added knowledge.

ApoE
CYP2C9
CYP2D6
CYP3A4
CYP3A5
CYP1A2
ABCB1
CYP2B6
CYP2C19
SLCO1B1
VKORC1
Factor II
Factor V
MTHFR

Phychiatry and Addiction

Drug Metabolism Panel

Purchase Phychiatry and Addiction Test Kit
This test targets the genotyping of 10 genes that are known to affect the metabolism of medications prescribed for psychiatric disorders and addiction drugs. It may help to understand why patients respond differently to drugs used in psychiatry and predict risk for psychiatric disorders, including neurodegenerative diseases and substance abuse. The panel aids in drug selection and dose planning for Antiaddictives, Anti-ADHD Agents, Anticonvulsants, Antidementia Agents, Antidepressants, Antipsychotics, Benzodiazepines, and other neurological agents.
CYP2B6
DRD2
CYP1A2
OPRM1
CYP2D6
CYP3A4
COMT
CYP2C19
CYP3A5
CYP2C9

Pain Medication

Metabolism Panel

Purchase Pain Medication Test Kit
This test targets the genotyping of 8 genes that are known to affect the metabolism of medications that treat pain and may aid in drug selection and dose planning for drugs metabolized by genes in the Pain Management Panel, including gene variants that affect pain threshold, presence of pain-related disorders (fibromyalgia, TMJ syndrome, migraine), and others. Medications covered under this panel include muscle relaxants, NSAIDs, opioids, and fibromyalgia agents.
CYP2C19
CYP3A4
CYP2C9
CYP1A2
CYP2D6
CYP3A5
OPRM1
COMT

Acid Reflux and Antiemetics

Drug Metabolism Panel

Purchase Acid Reflux & Antiemetics Test Kit
This test targets the genotyping of 6 genes that are known to affect the metabolism of medications that treat gastrointestinal disorders and may aid in drug selection and dose planning for drugs metabolized by genes in this panel, specifically gene variants that affect antiemetics and proton pump inhibitors.
CYP3A4
CYP1A2
CYP2C19
CYP2D6
CYP2C9
ABCB1

Anti-Seizure Medication

Metabolism Panel

Purchase Anti-Seizure Test Kit
This test targets the genotyping of 4 genes that are known to affect the metabolism of medications prescribed to treat seizures. There is a high variability in an individual’s response to antiepileptic treatment in which genetic variations play a major role. Our panel aids in drug selection and dose planning for anticonvulsants used in the treatment of epileptic seizures and to prevent the spread of the seizure within the brain.
CYP2C19
CYP3A4
CYP3A5
CYP2C9

Warfarin

Metabolism Panel

Purchase Warfarin Kit
This test targets the genotyping of 2 genes that are known to affect the metabolism of warfarin, one of the most prescribed blood thinners. One of the drawbacks of warfarin is that it is difficult to administer at the correct dose due to its narrow therapeutic index and its tendency to cause bleeding.

Achieving safe and effective doses of warfarin therapy is both an urgent and important concern for many clinicians and could be guided by the individual variability in patient response due to variants in CYP2C9, which codes for an enzyme that is primarily responsible for the metabolism of warfarin, and VKORC1, which codes for vitamin K epoxide reductase, a target for warfarin drug.

Plavix

Metabolism Panel

Purchase Plavix Kit
This test targets the genotyping of 1 gene that is known to affect the metabolism of Plavix (clopidogrel), a drug taken by about 40 million patients worldwide to prevent atherothrombotic events and cardiac stent thrombosis when given along with aspirin. Plavix is converted to its active form by CYP2C19 and certain variants in the gene produce an inactive enzyme which leads to poor or low metabolism of the drug. Other variants result in a fast-acting enzyme which is associated with rapid metabolism leading to faster clearing of the drug form the body. This test will identify those variants and help understand how Plavix is metabolized, which will lead to dose adjustments when needed and achieving better patient outcome.

Thrombosis Risk Panel

Factor II/V/MTHFR

Our Factor II-V & MTHFR Panel is a qualitative in vitro test that detects genotypes of Factor II, Factor V and MTHFR. It is indicated for use as an aid to diagnose patients with suspected thrombophilia. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens.

The most common variant associated with inherited thrombosis is Factor V Leiden G1691A variant. This variant results in resistance to activated protein C. The second most common variant associated with hereditary thrombosis is the G20210A variant in the prothrombin (Factor II) gene. This is associated with increased plasma prothrombin levels.

Increased plasma homocysteine levels is another important risk factor for venous thrombosis. An important genetic variant in the MTHFR gene is C677T the product of which is a thermolabile enzyme and decreased production of folate, a cofactor required for homocysteine remethylation. The MTHFR A1298C variant is also associated with increased homocysteine and lowered plasma folate levels when present in combination with the C677T mutation.

Our test detects the above described variants in each of Factor II, Factor V and MTHFR genes.

Factor II
Factor V
MTHFR

Orthopedic Panel

Orthopedic

This test may aid in drug selection and dose planning for drugs metabolized by genes in Orthopedic Panel: gene variants that affect pain threshold, presence of pain-related disorders (Fibromyalgia, TMJ syndrome), and Inherited Thrombosis.
CYP2C9
CYP2D6
MTHFR
Factor II
Factor V
VKORC1

CYP450 2C9

Sensitivity of Individuals to Drugs Metabolized by CYP450 2C9

Clinical Utility

The cytochrome P450 2C9 (CYP2C9) is involved in the metabolism of 15% of clinically important medications. This enzyme is highly polymorphic: to date, 30 variants have been identified. The CYP2C9 assay identifies some common variants that are associated with variability in CYP2C9 enzyme activity, which has important pharmacological and toxicological implications for anticonvulsants, anticoagulants, and certain antidiabetics.

Assay Interpretation

CYP2C9 enzyme activity defines a normal or abnormal (intermediate and poor) metabolizer status for a given individual. Several variant alleles have been identified and result in different CYP2C9 isoforms that functionally are fully active, partially active, or inactive. The CYP2C9*1 allele is considered wild-type and encodes a functionally active enzyme (normal). The alleles *2, *3, *4, *5, and *11 encode a partially active enzyme. The allele *6 is a null allele encoding for an inactive enzyme.

The genotype-phenotype relationship is established based on the allele’s activity. Individuals with two fully active alleles are considered normal (extensive) metabolizers. Individuals with one fully active allele with either a partially active or an inactive allele are considered intermediate metabolizers. Individuals with two partially active alleles or with two inactive alleles are considered poor metabolizers.

The reference range for CYP2C9 metabolic status is CYP2C9 *1/*1, which is consistent with a normal metabolizer.

Abnormal CYP2C9 activity affects the therapeutic outcome of a variety of drugs used to treat cardiovascular and other conditions. Following the administration of drug substrates, the clinical manifestation in a poor or an intermediate metabolizer depends on the characteristics of the drug (i.e., the amount of drug/metabolites that is cleared by the enzyme), and the safety and pharmacological profiles of the drug and its metabolites. Within the medications used to treat cardiovascular conditions, there is compelling evidence that the response to certain angiotensin II inhibitors, statins, and anticoagulants is altered in individuals exhibiting abnormal CYP2C9 activity.

CYP2C9 plays a role in the metabolism of the following psychotropic drugs: fluoxetine (Prozac), phenytoin (Dilantin), and primidone (Mysoline). Several NSAIDs and Cox-2 inhibitors are substrates of CYP2C9, and patients with reduced CYP2C9 activity may have higher plasma levels of celecoxib (Celebrex), flurbiprofen (Ocufen), piroxicam (Feldene), or meloxicam (Mobic). CYP2C9 plays a minor role in the elimination of diclofenac (Voltaren), sulindac (Clinoril), and naproxen (Aleve).

Cardiovascular medications that are metabolized by CYP2C9 include warfarin (Coumadin), fluvastatin (Lescol), losartan (Cozaar), and irbesartan (Avapro).

Other important drugs metabolized by CYP2C9 include antidiabetics such as tolbutamide,glibenclamide (Micronase), glipizide (Glucotrol), and nateglinide (Starlix).

Inhibitors or inducers of the CYP2C9 enzyme may modify its activity and change the patient’s metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2C9 inhibitors or inducers.

CYP450 2C9 *2
*3, *4, *5, *6, *11
Analgesic/Anesthesiology
Methadone
Anti-inflammatory
Celecoxib
Diclofenac
Anticoagulant/Antiplatelet
Warfarin
Cardiovascular
Azilsartan
Losartan
Verapamil
Endocrinology
Chlorpropamide
Glimepiride
Glyburide
Nateglinide
Tolbutamide
Infectious Disease
Quinine
Quinine Sulfate
Terbinafine
Neurology
Phenytoin
Oncology
Belinostat
Bortezomib
Gleevec
Imatinib
Urology
Vardenafil
Some known CYP2C9 inhibitors include: amiodarone (Cordarone), capecitabine (Xeloda), chloramphenicol, cimetidine (Tagamet), cotrimoxazole (Septra), danazol (Danocrine), delavirdine (Rescriptor), disulfiram (Antabuse), efavirenz (Sustiva), etravirine (Intelence), fluconazole (Diflucan), 5-fluorouracil (Adrucil), fluoxetine (Prozac), fluvastatin (Lescol), fluvoxamine (Luvox), gemfibrozil (Lopid), lomitapide (Juxtapid), metronidazole (Flagyl), miconazole (Oravig), oxandrolone (Oxandrin), phenytoin (Dilantin), sulfamethoxazole (Bactrim), sulfinpyrazone (Anturane), tamoxifen (Nolvadex), tigecycline (Tygacil), toremifene (Fareston), voriconazole (Vfend) and zafirlukast (Accolate).

Anticoagulant
Ticlopidine
Cardiovascular
Amiodarone
Fenofibrate
Fluvastatin
Lovastatin
Infectious Disease
Efavirenz
Fluconazole
Isoniazid
Sulfamethoxazole
Voriconazole
Oncology
Nilotinib
Teniposide
Psychiatry
Fluvoxamine
Paroxetine
Sertraline
Pulmonary
Zafirlukast

Some known CYP2C9 inducers include: aprepitant (Emend), bosentan (Tracleer), carbamazepine (Tegretol), dabrafenib (Tafinlar), elvitegravir (Genvoya, Stribild), enzalutamide (Xtandi), phenobarbital, phenytoin (Dilantin), primidone (Mysoline), rifampin (Rifadin, Rimactane), rifapentine (Priftin), ritonavir (Norvir) and St. John’s wort.

Gastroenterology
Aprepitant
Infectious Disease
Rifampin
Neurology
Phenobarbital
Oncology
Nilotinib
Sleep Medicine
Secobarbita

Fluoxetine (Prozac), phenytoin (Dilantin), and primidone (Mysoline). Several NSAIDs and Cox-2 inhibitors are substrates of CYP2C9, and patients with reduced CYP2C9 activity may have higher plasma levels of celecoxib (Celebrex), flurbiprofen (Ocufen), piroxicam (Feldene), or meloxicam (Mobic). CYP2C9 plays a minor role in the elimination of diclofenac (Voltaren), sulindac (Clinoril), and naproxen (Aleve).Cardiovascular medications that are metabolized by CYP2C9 include warfarin (Coumadin), fluvastatin (Lescol), losartan (Cozaar), and irbesartan (Avapro).

Other important drugs metabolized by CYP2C9 include antidiabetics such as tolbutamide,glibenclamide (Micronase), glipizide (Glucotrol), and nateglinide (Starlix).

Inhibitors or inducers of the CYP2C9 enzyme may modify its activity and change the patient’s metabolizer status. This can result in drug-drug interactions when a drug substrate is prescribed with known CYP2C9 inhibitors or inducers.

CYP450 3A4/3A5

Sensitivity of Individuals to Drugs Metabolized by CYP450 3A4/3A5 Genes

Our CYP450 3A4-3A5 Assay is a qualitative in vitro test that detects 13 clinically relevant genetic variants of CYP3A4 and CYP3A5 genes. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.
The CYP3A enzymes metabolize over 40% of the drugs currently approved by the FDA. Of the CYP3A enzymes, CYP3A4 and CYP3A5 are important in drug metabolism due to their abundance in the liver. This assay tests for common variants of CYP3A4 and CYP3A5 that can result in decreased metabolism of certain opioid analgesics (eg, buprenorphine, fentanyl, hydrocodone, meperidine, methadone) and other common drugs (eg, clonazepam and statins). This test may aid in drug selection and dose planning for drugs metabolized by CYP3A4 and CYP3A5.
CYP450 3A4 *1B,
*2, *3, *12
*17, CYP450 3A5
*1D, *2, *3
*3B, *6, *7,*8
and *9
ANTIHISTAMINES
astemizole
chlorpheniramine
ANTIMETRIC
aprepitant
ondansetron
ANESTHESIA/PAIN
cafergot
codeine-N-demethylation
fentanyl
levolevomethadyl acetate (LAAM)
lidocaine,
methadone
ANTIBIOTIC/ANTIVIRAL
alfentanil
boceprevir
clarithromycin
efavirenz
erythromycin (not CYP3A5)
indinavir
nelfinavir
nevirapine
quinine
ritonavir
saquinavir
telaprevir telithromycin.
CARDIOVASCULAR
amlodipine
cilostazol
diltiazem
eplerenone
lercanidipine
nifedipine
nisoldipine
nitrendipine
propranolol
quinidine (not CYP3A5)
verapamil
HMG COA REDUCTASE INHIBITORS
atorvastatin
lovastatin
simvastatin
IMMUNE MODULATORS
cyclosporine
sirolimus
tacrolimus
NEUROPSYCHIATRIC
alprazolam
diazepam
midazolam
triazolam
haloperidol
aripiprazole
buspirone
carbamazepine
pimozide
quetiapine
risperidone
trazodone
zaleplon
ziprasidone
zolpidem
ONCOLOGY
docetaxel
gleevec
irinotecan
paclitaxel
romidepsin
sorafenib
sunitinib
torisel
vemurafenib
vincristine
PULMONARY
salmeterol
sildenafil
STEROID
dexamethasone
estradiol
hydrocortisone
progesterone
testosterone
OTHER
cocaine
dapsone
dextromethorphan
finasteride
nateglinide
cocaine
dapsone
dextromethorphan
finasteride
nateglinide
STRONG INHIBITORS
clarithromycin
indinavir
itraconazole
ketoconazole
nefazodone
ritonavir
saquinavir
suboxone
telithromycin
INTERMEDIATE STRENGTH INHIBITORS
aprepitant
erythromycin
fluconazole
grapefruit juice
verapamil
diltiazem
WEAK INHIBITORS
cimetidine
OTHER POSSIBLE INHIBITORS
amiodarone
boceprevir
chloramphenicol
ciprofloxacin
delaviridine
diethyl-dithiocarbamate
fluvoxamine
gestodene
imatinib
mibefradil
mifepristone
norfloxacin
norfluoxetine
starfruit
telaprevir
voriconazole
barbiturates
carbamazepine
efavirenz
glucocorticoids
modafinil
nevirapine
oxcarbazepine
phenobarbital
phenytoin
pioglitazone
rifabutin
rifabutin
St. John’s Wort
troglitazone

CYP450 2C19

Sensitivity of Individuals to Drugs Metabolized by CYP450 2C19 Gene

Our CYP450 2C19 Assay is a qualitative in vitro test that detects mutations in CYP2C19 plus alleles, providing greater than 98% coverage of the variant alleles found for this gene.

This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.

This test may aid in drug selection and dose planning for drugs metabolized by CYP2C19 such as Plavix.
Drugs metabolized by CYP2C19 are antidepressants, antimalarials, clopidogrel, diazepam, phenytoin, proton pump inhibitors, R-warfarin, tamoxifen, etc.

CYP450 2C19
*2, *3, *4, *5
*6, *7, *8, *9
*10, *17
Analgesic/Anesthesiology
Methadone
Anticoagulant/Antiplatelet
Clopidogrel
Cardiovascular
Azilsartan
Cilostazol
Labetalol
Propranolol
Verapamil
Gastroenterology
Dexlansoprazole
Esomeprazole
Lansoprazole
Omeprazole
Ondansetron
Pantoprazole
Rabeprazole
Infectious Disease
Nelfinavir
Quinine
Quinine Sulfate
Terbinafine
Voriconazole
Neurology
Clobazam
Oncology
Bortezomib
Gleevec
Imatinib
Lapatinib
Psychiatry
Amitriptyline
Citalopram
Clomipramine
Diazepam
Escitalopram
Imipramine
Milnacipran
Sertraline
Trimipramine
Vortioxetine
Rheumatology
Carisoprodol
Tofacitinib
Anesthesiology/Analgesic
Indomethacin
Methadone
Phenylbutazone
Gastroenterology
Cimetidine
Esomeprazole
Lansoprazole
Metoclopramide
Omeprazole
Pantoprazole
Rabeprazole
Infectious Disease
Chloramphenicol
Efavirenz
Isoniazid
Ketoconazole
Voriconazole
Neurology
Eslicarbazepine
Felbamate
Oxcarbazepine
Topiramate
Psychiatry
Fluoxetine
Fluvoxamine
Rheumatology
Probenecid
Sleep Medicine
Modafinil
Infectious Disease
Rifampin
Neurology
Carbamazepine

CYP450 2D6

Sensitivity of Individuals to Drugs Metabolized by CYP450 2D6 Gene

Our CYP450 2D6-BC Assay is a qualitative in vitro test that detects mutations in CYP450 2D6. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.
CYP2D6 is one of the most important drug metabolizing enzyme genes as it metabolizes 25% to 30% of all prescribed drugs. Common drug categories metabolized by CYP2D6 include beta blockers, anti-arrhythmic, morphine derivatives, and antidepressants.
This test may aid in drug selection and dose planning for drugs metabolized by CYP450 2D6.
CYP450 2D6 *2
*3, *4, *5, *6,
*7, *8, *9, *10
*12, *14, *17
*29, *41, XN
Analgesic/Anesthesiology
Codeine
Cyclobenzaprine
Hydrocodone
Methadone
Oxycodone
Tramadol
Cardiovascular
Carvedilol
Clonidine
Flecainide
Lidocaine
Metoprolol
Propafenone
Propranolol
Ranolazine
Timolol
Infectious Disease
Quinine
Quinine Sulfate
Neurology
Donepezil
Tetrabenazine
Oncology
Bortezomib
Gleevec
Imatinib
Tamoxifen
Psychiatry
Amitriptyline
Aripiprazole
Atomoxetine
Brexpiprazole
Buproprion
Clomipramine
Clozapine
Desipramine
Diazepam
Doxepin
Duloxetine
Fluoxetine
Fluvoxamine
Haloperidol
Iloperidone
Imipramine
Milnacipran
Nortriptyline
Olanzapine
Paroxetine
Perphenazine
Pimozide
Protriptyline
Quetiapine
Risperidone
Thioridazine
Trimipramine
Venlafaxine
Vortioxetine
Rheumatology
Cevimeline
Urology
Tamsulosin
Tolterodine
Allergy
Chlorpheniramine
Clemastine
Diphenhydramine
Hydroxyzine
Anesthesiology/Analgesic
Celecoxib
Dexmedetomidine
Anticoagulant
Ticlopidine
Cardiovascular
Amiodarone
Dronedarone
Midodrine
Quinidine
Drug of Abuse
Cocaine
Endocrinology
Cinacalcet
Endocrinology
Cimetidine
Ranitidine
Infectious Disease
Quinine Sulfate
Ritonavir
Terbinafine
Oncology
Doxorubicin
Nilotinib
Pazopanib
Psychiatry
Bupropion
Chlorpromazine
Citalopram
Clomipramine
Duloxetine
Escitalopram
Fluoxetine
Fluvoxamine
Haloperidol
Paroxetine
Sertraline
Infectious Disease
Rifampin

CYP450 2B6

Sensitivity of Individuals to Drugs Metabolized by CYP450 2B6 Gene

Our CYP450 2B6 QUAD-96 Assay is a qualitative in vitro test that detects 7 genetic variants of the CYP2B6 gene. This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash. It can detect and identify the following allelic variants: 64C>T, 983T>C, 415 A>G, 1132 C>T, 516 G>T, 1459 C>T, 785 A>G.
The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide, opioid analgesic, antidepressants, NNRTI, opiate replacement therapy, anesthetic, protein kinase inhibitor, SERM, and others.
64C>T
983T>C
415 A>G
1132 C>T
516 G>T
1459 C>T
785 A>G

CYP450 1A2

Sensitivity of Individuals to Drugs Metabolized by CYP450 1A2 Gene

Our CYP450 1A2-96 Assay is a qualitative in vitro test that is designed to detect mutations in the CYP1A2 gene.

This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash.

It is designed to detect and identify three allelic variants in the CYP450 1A2 gene.
This gene affects the metabolism of common antidepressant and antipsychotic medications.

3860G>A
163C>A
2467delT

ApoE

Sensitivity of Individuals to Statins

Our ApoE QUAD Assay is a qualitative in vitro test that is designed to detect mutations in the ApoE gene.

This assay is performed using genomic DNA isolated from human peripheral whole blood specimens or buccal cells from mouthwash. It can detect and identify the following allelic variants in the ApoE gene: 388T>C and 526C>T and report the predicte isoforms on the high throughput system.
The predicted isoform call can be: [E3,E3], [E2,E3], [E2,E2], [E3,E4], [E4,E4], or [E2,E4].

These genetic variants affect the response to statins.

If you have any questions about Ayass BioScience, LLC (DBA Ayass Lung Clinic, PLLC – CLIA Certified Laboratory) Pharmacogenetic Testing, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.